- Home
- SEZL vs MNKD Comparison
SEZL vs MNKD Comparison
Compare SEZL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEZL | MNKD |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | SEZL | MNKD |
|---|---|---|
| Price | $72.07 | $5.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $131.67 | $10.08 |
| AVG Volume (30 Days) | 982.1K | ★ 3.4M |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.61 | 23.47 |
| EPS | ★ 3.24 | 0.10 |
| Revenue | ★ $418,632,890.00 | $313,787,000.00 |
| Revenue This Year | $68.97 | $21.54 |
| Revenue Next Year | $26.02 | $22.21 |
| P/E Ratio | ★ $21.38 | $57.41 |
| Revenue Growth | ★ 88.74 | 17.43 |
| 52 Week Low | $24.86 | $3.38 |
| 52 Week High | $186.74 | $6.58 |
Technical Indicators
Market Signals| Indicator | SEZL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 47.67 |
| Support Level | $62.85 | $5.53 |
| Resistance Level | $72.39 | $6.12 |
| Average True Range (ATR) | 4.15 | 0.16 |
| MACD | -0.41 | -0.05 |
| Stochastic Oscillator | 63.07 | 20.49 |
Price Performance
Historical ComparisonAbout SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.